New Long-Read Genetic Test Enables Faster and More Comprehensive Diagnosis of Rare Diseases
November 18, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Moxifloxacin systemic, Avelox
Synonyms :
Moxifloxacin
Class :
fluoroquinolones
Brand Name :
Moxifloxacin systemic, Avelox
Synonyms :
Moxifloxacin
Class :
fluoroquinolones
Dosage Forms & StrengthsÂ
Injectable solutionÂ
400mg/250mlÂ
TabletÂ
400mgÂ
400
mg
Tablet
Intravenous (IV)
every day
7 - 14
days
Complicated: 400mg orally intravenous every day for 7-21 day
Uncomplicated: 400mg orally intravenous every day for seven days
400mg orally intravenous every day for 5-10 days
Pneumonia And Septicemia PlaqueÂ
400mg orally/intravenous every day for 10-14 days
chronic exacerbation
:
400mg orally/intravenous every day for five days
400mg orally/intravenous every day for 5-14 days
400mg orally/intravenous every day
Dosage Forms & StrengthsÂ
<18 years: Safety and efficacy not establishedÂ
Refer adult dosingÂ
may diminish the quinolones absorption
may diminish the quinolones absorption
may diminish the quinolones absorption
may diminish the quinolones absorption
may diminish the quinolones absorption
may decrease the therapeutic effect of antibiotics
may increase the Qt prolonging effect
may diminish the serum concentration of quinolones
may diminish the quinolones absorption
may diminish the quinolones absorption
may increase the Qtc prolonging effect
may increase the Qtc prolonging effect
may increase the Qtc prolonging effect
may increase the Qtc prolonging effect
may increase the Qtc prolonging effect
may increase the photosensitizing agents
may increase the Qt prolonging effect
may diminish the quinolones absorption
may have an increased QTc-prolonging effect when combined with moxifloxacin
may have an increased QTc-prolonging effect when combined with moxifloxacin
moxifloxacin: they may increase the QTc-prolonging effect of QTc-prolonging Agents
moxifloxacin: they may increase the QTc-prolonging effect of QTc-prolonging Agents
moxifloxacin: they may increase the QTc-prolonging effect of QTc-prolonging Agents
moxifloxacin: they may increase the QTc-prolonging effect of QTc-prolonging Agents
QTc interval is increased both by lenvatinib and moxifloxacin
may decrease the serum concentration of activated charcoal
the toxicity of either of the drugs is increased due to pharmacokinetic synergism
may enhance the QTc-prolonging effect of Moxifloxacin
may enhance the QTc-prolonging effect of Moxifloxacin
may enhance the QTc-prolonging effect of Moxifloxacin
may enhance the QTc-prolonging effect of Moxifloxacin
may enhance the QTc-prolonging effect of Moxifloxacin
may increase the Qtc prolonging effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the toxic effects
may increase the toxic effects
may increase the toxic effects
may increase the toxic effects
may increase the toxic effects
may increase the anticoagulant effect
may increase the anticoagulant effect
may increase the anticoagulant effect
may increase the anticoagulant effect
may increase the anticoagulant effect
may diminish the serum concentration of quinolones
may increase the cardiotoxic effect
The presence of magnesium hydroxide reduces moxifloxacin levels by inhibiting its gastrointestinal absorption
trimagnesium citrate anhydrousÂ
trimagnesium citrate anhydrous hinders the gastrointestinal absorption of moxifloxacin, leading to decreased levels
when bromazepam and moxifloxacin are used together, there is a potential reduction in the bromazepam's metabolism
may decrease the serum concentration and decrease in the efficacy
may increase the QTc prolonging effect of QT-prolonging agents
the toxicity of either of the drugs is increased due to pharmacokinetic synergism
When moxifloxacin is aided by hesperetin, it reduces hesperetin’s metabolism
when both drugs are combined, there may be an increased level of serum of moxifloxacin 
when both the drugs are combined, the metabolism of carmustine decreases    
it enhances the effect of alprazolam by diminishing the metabolism
may enhance the levels of clorazepate by decreasing the metabolism
Frequency defined:Â Â
1-10%Â
DiarrheaÂ
Decreased amylaseÂ
Decreased serum glucoseÂ
Increased serum ionized calciumÂ
NauseaÂ
DizzinessÂ
Decreased basophilsÂ
Increased serum chlorideÂ
Increased serum ionized calciumÂ
Prolonged QT intervalÂ
<1%Â
AgranulocytosisÂ
Aplastic anemiaÂ
Extrinsic allergic alveolitisÂ
Hepatic failureÂ
HepatitisÂ
SeizureÂ
Stevens-Johnson syndromeÂ
ThrombocytopeniaÂ
Toxic epidermal necrolysisÂ
Acute renal failureÂ
Anaphylactoid reactionÂ
Hemolytic anemiaÂ
PancytopeniaÂ
Serum sickness due to drugÂ
Tendon ruptureÂ
Post-marketing reportsÂ
AgranulocytosisÂ
Aortic aneurysmÂ
HepatitisÂ
Tendon ruptureÂ
HallucinationsÂ
Renal dysfunctionÂ
Peripheral neuropathyÂ
DepressionÂ
ConfusionÂ
Pregnancy consideration: Insufficient data availableÂ
Lactation: Excretion of the drug in human breast milk is unknownÂ
Pregnancy category:Â
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.  Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.   Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this categoryÂ
Patient information leafletÂ
Generic Name: moxifloxacinÂ
Pronounced: (mox-ih-FLOX-uh-sin)Â
Why do we use moxifloxacin?Â
Moxifloxacin is an antibiotic that is used to treat a variety of infections caused by bacteria. It belongs to a class of antibiotics called fluoroquinolones.Â
Moxifloxacin is used to treat respiratory tract infections, including pneumonia and bronchitis. It can also treat skin and soft tissue infections and urinary tract infections. Moxifloxacin is usually taken by mouth as a tablet or oral suspension. Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
